Edition:
India

Castle Biosciences Inc (CSTL.OQ)

CSTL.OQ on NASDAQ Stock Exchange Global Market

41.36USD
10:53pm IST
Change (% chg)

$-0.82 (-1.94%)
Prev Close
$42.18
Open
$42.40
Day's High
$42.40
Day's Low
$40.88
Volume
14,935
Avg. Vol
64,606
52-wk High
$45.26
52-wk Low
$15.32

Summary

Name Age Since Current Position

Daniel Bradbury

59 2014 Independent Chairman of the Board

Derek Maetzold

58 2017 President, Chief Executive Officer, Founder, Director

Frank Stokes

50 2017 Chief Financial Officer

Toby Juvenal

2018 Senior Vice President - Sales

Kristen Oelschlager

2018 Senior Vice President - Clinical Operations

Alice Izzo

2018 Vice President - Marketing

Bob Cook

2019 Vice President - Research & Development

Michael Maltby

2018 Executive Director - Managed Care

Noreen Manning

2018 Executive Director - Reimbursement

Bernhard Spiess

60 2019 Chief Business Officer

Bonnie Anderson

62 2015 Independent Director

Mara Aspinall

57 2015 Independent Director

G. Bradley Cole

64 2018 Independent Director

Joseph Cook

49 2018 Independent Director

Miles Harrison

55 2020 Independent Director

David Kabakoff

72 2017 Independent Director

Biographies

Name Description

Daniel Bradbury

Mr. Daniel Mark Bradbury serves as Independent Chairman of the Board of the Company. Since January 2020, Mr. Bradbury has served as Executive Chairman of Equillium, Inc., a publicly traded biotechnology company where he also served as its Chief Executive Officer from June 2018 to December 2019 and as its President from March 2017 until June 2018. Mr. Bradbury is the founder of, and has served as the managing member of, BioBrit, LLC, a life sciences consulting and investment firm, since September 2012. Mr. Bradbury served as President, Chief Executive Officer and a director of Amylin Pharmaceuticals, Inc., from March 2007 until Amylin’s acquisition by Bristol-Myers Squibb Company in August 2012. Prior to Amylin, Mr. Bradbury worked in marketing and sales for ten years at SmithKline Beecham Pharmaceuticals. Mr. Bradbury serves on the board of directors of numerous private companies and two other publicly traded companies, Equillium, Inc. and Intercept Pharmaceuticals, Inc. Mr. Bradbury previously served on the board of directors of the following publicly traded companies: Corcept Therapeutics, Inc., from 2012 to 2019; Geron Corporation, from 2012 to 2019; and Illumina, Inc. from 2004 to 2017. Mr. Bradbury holds a Bachelor of Pharmacy degree from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.

Derek Maetzold

Mr. Derek J. Maetzold serves as President, Chief Executive Officer, Founder, Director of the Company. Previously, Mr. Maetzold held leadership roles at Encysive Pharmaceuticals, Schering-Plough Corporation (now Merck), Integrated Communications, Amylin Pharmaceuticals and Sandoz Pharmaceuticals (now a division of Novartis). Mr. Maetzold currently serves as a director of the Ocular Melanoma Foundation. He has contributed to the discovery, development and commercialization of five diagnostic and prognostic tests in cancers, has co-authored multiple scientific publications and is a co-inventor of a number of technologies at Castle Biosciences and Encysive Pharmaceuticals. Mr. Maetzold holds a B.S. degree in Biology from George Mason University and completed additional coursework at the University of Calgary Health Sciences Center and the MBA program at the University of California, Riverside.

Frank Stokes

Mr. Frank Stokes serves as Chief Financial Officer of the Company. From January 2017 to December 2017, Mr. Stokes served as Chief Financial Officer of Hammock Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of women’s health and urology products. From May 2011 to December 2016, Mr. Stokes served as a Managing Director of Leerink Swann (now SVB Leerink). Mr. Stokes also held positions as a Managing Director at Robert W. Baird & Co. Incorporated and Wachovia Securities, LLC. While at SVB Leerink and Robert W. Baird & Co., Mr. Stokes led life sciences, tools and diagnostics sector investment banking efforts, and managed financings and mergers and acquisitions transactions. Mr. Stokes holds a B.S. degree in Business Administration and J.D. and MBA degrees from the University of North Carolina at Chapel Hill.

Toby Juvenal

Mr. Toby Juvenal serves as Senior Vice President - Sales of the Company. Mr. Toby Juvenal has over 20 years of sales, sales management, and managed care experience in the pharmaceutical, biotechnology and diagnostics industries. In his current role, Toby leads the Company’s sales efforts, and has been instrumental in the acceleration of sales growth in recent years. Toby joined Castle Biosciences in 2008 as one of three initial employees. Prior to Castle, he held management positions at deCODE Genetics, Encysive Pharmaceuticals and Genzyme Pharmaceuticals. He began his career at Stuart Pharmaceuticals (now AstraZeneca). Toby attended the University of Florida where he received a B.S. in Marketing.

Kristen Oelschlager

Ms. Kristen Oelschlager serves as Senior Vice President - Clinical Operations of the Company. Ms. Kristen Oelschlager has served as our Senior Vice President, Clinical Operations since January 2018, previously serving as our Vice President, Clinical Operations from 2013 to 2018, and as our Executive Director of Clinical Operations when she joined the company as one of three initial employees. Ms. Oelschlager brought more than 15 years of experience in clinical nursing, clinical operations services, and clinical research to her position. She has successfully overseen the growth and development of Castle’s laboratory and clinical research functions from early start-up to full commercial operations. Prior to joining Castle, Ms. Oelschlager held senior roles in research operations, including the start-up and growth management of a multi-specialty clinical research department as Director of Clinical Research of Arizona Pulmonary Specialists. Ms. Oelschlager has held Speaker’s Bureau appointments for Actelion Pharmaceuticals, Eli Lilly, and Encysive Pharmaceuticals, has co-authored numerous publications and is a co-inventor of several of Castle Biosciences’ technologies. Ms. Oelschlager attended Purdue University, where she completed core nursing requirements concurrent to receiving an Associate of Science, Nursing from the Indiana Vocational Technical College.

Alice Izzo

Ms. Alice Izzo serves as Vice President - Marketing of the Company. Ms. Alice Izzo has served as our Vice President, Marketing since March 2018, previously serving as our Executive Director, Marketing since joining the company in September 2013. In her current position, Ms. Izzo has responsibility for marketing, public relations and communications. Prior to Castle, Ms. Izzo held various leadership positions at Amylin Pharmaceuticals including Vice President of Corporate Affairs from 2010 until the company’s purchase in 2012. She previously served as Executive Director, Investor Relations, and held marketing, clinical development, and project management roles at the company. Ms. Izzo has previously served in operational roles in medical communication companies, including Vice President of Operations at a successful start-up. Ms. Izzo attended Duquesne University where she obtained a B.S. degree in pharmacy before receiving her MBA in Marketing from Saint Joseph’s University.

Bob Cook

Dr. Bob Cook Ph.D. serves as Vice President - Research & Development of the Company. Bob Cook serves as Vice President - Research & Development of the Company. Bob Cook serves as Vice President - Research & Development of the Company. Dr. Bob Cook has served as our Vice President, Research & Development since July 2019, and previously served as our Vice President, Medical Affairs and R&D from April 2018 to July 2019, Executive Director, R&D from June 2015 to April 2018, and Manager of Scientific Relations from February 2011 to June 2015. Dr. Cook joined Castle Biosciences following a postdoctoral fellowship at Baylor College of Medicine where he focused on the genetic regulation of rare ovarian granulosa cell tumors. In his current position, Dr. Cook oversees research and development at Castle. He previously completed his doctoral work in Biochemistry, Molecular Biology and Cellular Biology at Northwestern University, with a focus on the structural characteristics of protein hormones important for regulating the reproductive system. Prior to pursuing his doctoral degree, Dr. Cook spent five years at Gen-Probe, Inc., using the company’s proprietary nucleic acid amplification technology to design diagnostic assays for hematologic malignancies and solid tumors. He received a B.S. Degree in Molecular Biology from Temple University in Philadelphia. Dr. Cook is an author of many medical and scientific publications and a co-inventor of several of Castle Biosciences’ technologies.

Michael Maltby

Mr. Michael Maltby serves as Executive Director - Managed Care of the Company. Michael Maltby serves as Executive Director - Managed Care of the Company. Michael Maltby serves as Executive Director - Managed Care of the Company. Mr. Michael Maltby has served as our Executive Director, Managed Care since December 2018. He has over 25 years of experience in the pharmaceutical, diagnostics, and health care industries, previously serving as Senior Director of Managed Care at MDxHealth, Inc. from May 2015 to November 2018, and Director of Managed Care at CardioDx from February 2014 to May 2015. He has also held various positions at Pacific Edge Diagnostics USA, Ltd., Sequenom Center for Molecular Medicine, Prometheus Therapeutics & Diagnostics, and Automata. Mr. Maltby has supported teams in collaboration across the sales, medical affairs and reimbursement functions to drive improvements in marketed and pipeline products. Mr. Maltby received a B.S. degree in AgriBusiness from Delaware Valley College of Science and Agriculture in Pennsylvania.

Noreen Manning

Ms. Noreen Manning serves as Executive Director - Reimbursement of the Company. Ms. Noreen Manning has served as our Executive Director, Reimbursement since April 2018, previously serving as our Director, Reimbursement since joining the company in May 2014. Ms. Manning brought more than 15 years of experience in medical billing and project management. In her current position, Ms. Manning oversees billing operations, and payer policy and contract implementation. She has successfully grown this function at Castle to meet increased needs for payor engagement and communication. Prior to Castle, Ms. Manning was the Associate Director of Reimbursement at Indi (Integrated Diagnostics, Inc.), and an Account Executive at Quadax, Inc. Ms. Manning’s work specializes in the design, implementation and management of reimbursement programs for molecular diagnostic start-up laboratories.

Bernhard Spiess

Mr. Bernhard E. Spiess serves as Chief Business Officer of the Company. Mr. Bernhard E. Spiess was our Chief Operating Officer from May 2016 to September 2019. From April 1997 to April 2016, Mr. Spiess held various positions with Beckman Coulter, Inc., a manufacturer of biomedical testing instrument systems, tests and supplies, including as Vice President, Strategic Marketing, Blood Virus & Infectious Diseases from February 2015 to April 2016, and as Vice President, Marketing, Molecular Diagnostics from April 2008 to February 2015. Throughout his career, Mr. Spiess has held positions of increasing responsibility in laboratory testing and management, scientific support, sales, strategic and tactical marketing, and product and business management. Mr. Spiess holds a B.App.Sc. degree in Medical Technology from the Royal Melbourne Institute of Technology.

Bonnie Anderson

Ms. Bonnie H. Anderson serves as Independent Director of the Company. Since February 2008, Ms. Anderson has served as the Chief Executive Officer and as a member of the board of directors of Veracyte, Inc., a publicly traded genomic diagnostics company, and as the chairman of Veracyte’s board of directors, since December 2016. From August 2013 to February 2017, she also served as Veracyte’s President. Prior to Veracyte, Ms. Anderson was an independent strategic consultant from April 2006 to January 2008. Ms. Anderson was a Vice President at Beckman Coulter, Inc., a manufacturer of biomedical testing instrument systems, tests and supplies, from September 2000 to March 2006. In addition to her positions with Veracyte, Ms. Anderson currently serves as a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. Ms. Anderson holds a B.S. degree in Medical Technology from Indiana University of Pennsylvania.

Mara Aspinall

Ms. Mara Glickman Aspinall serves as Independent Director of the Company. Ms. Aspinall has served as Managing Director of BlueStone Venture Partners, a life science-focused venture capital firm, since December 2017. Since June 2014, Ms. Aspinall has served as the Managing Member of Health Catalysts Group, a consulting firm that focuses on growth of early-stage life science and technology companies. From September 2011 until June 2014, Ms. Aspinall served as the President and Chief Executive Officer of the Ventana Medical Systems and the Global Head of Roche Tissue Diagnostics, a global leader in the development and commercialization of tissue-based cancer diagnostics. Prior to 2011, Ms. Aspinall served as President of Genzyme Pharmaceuticals and Genzyme Genetics. Ms. Aspinall currently serves as a director of Allscripts Healthcare Solutions, Orasure Technologies and UK-based company Abcam plc., along with other privately held healthcare technology and medical insurance companies. Ms. Aspinall holds a B.A. degree in International Relations from Tufts University and an MBA from Harvard Business School. Ms. Aspinall is certified in board oversight of cybersecurity from the National Association of Corporate Directors and Carnegie Mellon University.

G. Bradley Cole

Mr. G. Bradley Cole serves as Independent Director of the Company. Since November 2019, Mr. Cole has served as General Manager, Precision Oncology, a unit of Exact Sciences Corporation, a molecular diagnostics company, following Exact Science Corporation’s acquisition of Genomic Health, Inc. in November 2019. From June 2004 to November 2019, Mr. Cole served as Chief Financial Officer of Genomic Health, Inc., a publicly traded global provider of genomic-based diagnostic tests, where he also served as Chief Operating Officer from January 2009 until March 2018. Mr. Cole previously held Chief Financial Officer positions at multiple publicly traded companies, including Applied Biosystems, Inc. Mr. Cole holds a B.S. degree in Accounting from Biola University and an MBA from San Jose State University.

Joseph Cook

Mr. Joseph C. Cook III, Jr. serves as Independent Director of the Company. Since February 2003, Mr. Cook has served as a Managing Director at Mountain Group Partners, an investment firm with investments in the life sciences, agtech and technology sectors. From January 2001 until February 2003, Mr. Cook served as a Director, Private Placements in the Investment Banking Group of Robert W. Baird & Co. Incorporated. Mr. Cook also previously served as a Vice President in the Investment Banking Group at J.C. Bradford & Co. Mr. Cook serves on the board of directors of MiNDERA Corp., a non-invasive transcriptome testing company, and Cerebrotech Medical Systems, Inc., a machine learning cerebral diagnostic company. Mr. Cook holds a B.A. degree in Economics from Davidson College.

Miles Harrison

Mr. Miles D. Harrison serves as Independent Director of the Company. Since February 2016, Mr. Harrison has served as the North American president and general manager of Galderma Laboratories, L.P., the largest independent global dermatology company. Mr. Harrison also served as Galderma’s vice president and general manager of the Consumer Business Unit from August 2014 until February 2016. Prior to Galderma, Mr. Harrison spent most of his career at Novartis, a healthcare company. From June 1987 until February 2014, Mr. Harrison held multiple leadership positions of increasing responsibility across the consumer, oncology and pharmaceuticals businesses, most recently as vice president and head of global advocacy. Mr. Harrison holds a B.A. degree (Honors) in Geography from Sheffield Hallam University in the United Kingdom.

David Kabakoff

Dr. David S. Kabakoff Ph.D. serves as Independent Director of the Company. Since 2012, Dr. Kabakoff has served as a partner at HealthQuest Capital, an investment firm. Since 2007, Dr. Kabakoff has also served as an executive partner at Sofinnova Ventures, an investment firm. Dr. Kabakoff’s currently serves as chairman of the board of directors of NextCure, Inc., a publicly traded biopharmaceutical company. Dr. Kabakoff also serves on the board of directors of numerous private companies, including Antiva Biosciences, Inc., a biopharmaceutical company, Dauntless Pharmaceuticals, a biopharmaceutical company, Lineagen (chairman), a genetic testing company, bioTheranostics, a molecular diagnostics company, Rainier Therapeutics, Inc., a biopharmaceutical company and Neurana Pharmaceuticals, Inc., a biopharmaceutical company. From 2006 until October 2014, Dr. Kabakoff served on the board of directors of InterMune Inc., a publicly traded biopharmaceutical company. In 2001 Dr. Kabakoff co-founded Salmedix, Inc., a developer of cancer drug treatments, served as its Chairman and Chief Executive Officer and led its acquisition in June 2005 by Cephalon, Inc. From 1996 to 2000, Dr. Kabakoff held the positions of Executive Vice President of Dura Pharmaceuticals, Inc. and President and Chief Executive Officer of Spiros, both pharmaceutical companies. From 1989 to 1996, Dr. Kabakoff was employed as Chief Executive Officer of Corvas International, Inc., a developer of biotherapeutics, and from 1983 to 1989 held senior executive positions with Hybritech, a biotechnology company. Dr. Kabakoff holds a B.A. degree in Chemistry from Case Western Reserve University and a Ph.D. from Yale University.